These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 6480380)

  • 1. Evaluation of estrogen dependency of human breast cancers. II. Clinical evaluation of tamoxifen in advanced primary and recurrent breast cancer.
    Nishiki M; Yamane M; Amano K; Yasuda K; Okumichi T; Ezaki H
    Hiroshima J Med Sci; 1984 Jun; 33(2):163-6. PubMed ID: 6480380
    [No Abstract]   [Full Text] [Related]  

  • 2. [Tamoxifen therapy in locally advanced primary and recurrent breast cancer (author's transl)].
    Wada T; Koyama H; Takahashi Y; Nishizawa Y; Iwanaga T; Aoki Y; Terasawa T
    Nihon Gan Chiryo Gakkai Shi; 1979 Aug; 14(5):819-24. PubMed ID: 501187
    [No Abstract]   [Full Text] [Related]  

  • 3. [Tamoxifen: modern drug therapy of estrogen-dependent breast tumors].
    Jovanović-Mićić D; Beleslin DB; Nikolić SS
    Med Pregl; 1996; 49(7-8):287-90. PubMed ID: 8926945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The nature of tamoxifen action in the control of female breast cancer.
    Kodama M; Kodama T
    In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE
    Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superiority of letrozole over tamoxifen in the first-line treatment of metastatic breast cancer patients with normal serum Her-2/neu levels: question of tamoxifen resistance.
    Altundag K; Altundag O
    J Clin Oncol; 2003 Dec; 21(24):4656; author reply 4657. PubMed ID: 14673060
    [No Abstract]   [Full Text] [Related]  

  • 8. [Results of anti-estrogen therapy in metastatic breast cancer (preliminary results). Part II].
    Firusian N; Schmidt CG
    Med Welt; 1977 Dec; 28(51-52):2065-7. PubMed ID: 414049
    [No Abstract]   [Full Text] [Related]  

  • 9. Physicians' assessments of adjuvant tamoxifen's effectiveness in older patients with primary breast cancer.
    Lash TL; Gurwitz JH; Silliman RA
    J Am Geriatr Soc; 2005 Nov; 53(11):1889-96. PubMed ID: 16274369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
    Newby JC; Johnston SR; Smith IE; Dowsett M
    Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
    Meijer-van Gelder ME; Look MP; Peters HA; Schmitt M; Brünner N; Harbeck N; Klijn JG; Foekens JA
    Cancer Res; 2004 Jul; 64(13):4563-8. PubMed ID: 15231667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Superiority of letrozole compared with tamoxifen as first line therapy of postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group].
    Illiger HJ
    Strahlenther Onkol; 2002 Feb; 178(2):111-3. PubMed ID: 11942036
    [No Abstract]   [Full Text] [Related]  

  • 13. [Basic Consensus on endocrinotherapy for breast cancer].
    Jiang ZF; Xu BH; Song ST
    Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):238-9. PubMed ID: 16875616
    [No Abstract]   [Full Text] [Related]  

  • 14. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
    Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
    Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary endocrine therapy in locally advanced breast cancers--the Nottingham experience.
    Mathew J; Agrawal A; Asgeirsson KS; Buhari SA; Jackson LR; Cheung KL; Robertson JF
    Breast Cancer Res Treat; 2009 Jan; 113(2):403-7. PubMed ID: 18311583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of estrogen dependency of human breast cancers. I. Cytochemical study of estrogen receptor in human breast cancer tissue.
    Nishiki M; Yamane M; Amano K; Yasuda K; Okumichi T; Ezaki H
    Hiroshima J Med Sci; 1984 Jun; 33(2):157-61. PubMed ID: 6090348
    [No Abstract]   [Full Text] [Related]  

  • 17. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
    Lipton A; Ali SM; Leitzel K; Demers L; Harvey HA; Chaudri-Ross HA; Brady C; Wyld P; Carney W
    J Clin Oncol; 2003 May; 21(10):1967-72. PubMed ID: 12743150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.
    Andre F; Hatzis C; Anderson K; Sotiriou C; Mazouni C; Mejia J; Wang B; Hortobagyi GN; Symmans WF; Pusztai L
    Clin Cancer Res; 2007 Apr; 13(7):2061-7. PubMed ID: 17404087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy.
    Toi M; Ikeda T; Akiyama F; Kurosumi M; Tsuda H; Sakamoto G; Abe O
    Int J Oncol; 2007 Oct; 31(4):899-906. PubMed ID: 17786323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reliability of immunocytochemical assay of estrogen receptors on breast cancer aspirates as a predictor of clinical response to hormone therapy.
    Ciatto S; Pacini P; Confortini M; Massimo V
    Acta Cytol; 1994; 38(4):666-7. PubMed ID: 8042436
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.